Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects

被引:14
|
作者
Tsukahara, Kengo [1 ]
Kimura, Kazuo [1 ]
Morita, Satoshi [1 ]
Ebina, Toshiaki [1 ]
Kosuge, Masami [1 ]
Hibi, Kiyoshi [1 ]
Iwahashi, Noriaki [1 ]
Endo, Mitsuaki [1 ]
Maejima, Nobuhiko [1 ]
Sugano, Teruyasu [1 ]
Umemura, Satoshi [1 ]
机构
[1] Yokohama City Univ, Med Ctr, Div Cardiol, Minami Ku, Yokohama, Kanagawa 2320024, Japan
关键词
Platelet inhibitors; Drug interactions; Coronary artery disease; PERCUTANEOUS CORONARY INTERVENTION; ELUTING STENT THROMBOSIS; PLATELET REACTIVITY; INCREASED RISK; CLOPIDOGREL RESISTANCE; CARDIOVASCULAR EVENTS; HEALTHY-SUBJECTS; THERAPY; ASPIRIN; RESPONSIVENESS;
D O I
10.1016/j.jjcc.2011.01.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although there has been an intense debate whether concomitant use of proton-pump inhibitors (PPIs) attenuates the antiplatelet effects of thienopyridine derivatives, the drug drug interaction remains unclear in Japanese patients with coronary artery disease. Methods and results: Platelet function test was performed in 461 patients who were scheduled for or had undergone stent implantation, treated with 100 mg/day of aspirin and a thienopyridine (200 mg/day of ticlopidine or 75 mg/day of clopidogrel) for at least 14 days. Adenosine diphosphate-induced platelet aggregation was evaluated with screen filtration pressure method, and the upper quartile of high platelet reactivity was defined as high on-treatment platelet reactivity (HPR). PPI use was at physician's discretion. Patients taking a thienopyridine plus a PPI (n = 166) were older and had a higher incidence of acute coronary syndromes on admission compared with patients taking a thienopyridine without a PPI (n = 295). The rate of HPR was higher in patients taking a thienopyridine plus a PPI than in patients taking a thienopyridine without a PPI (31% vs 21%, p=0.01). On multivariate logistic regression analysis, independent predictors of HPR were concomitant PPI use [odds ratio (OR): 1:66, 95% confidence interval (CI): 1.03-2.68], diabetes mellitus (OR: 1.76, CI: 1.11-2.81), and calcium channel blockers use (OR: 1.93, CI: 1.18-3.18). However, there was no significant difference in the rate of extremely high platelet reactivity [58 patients (12.5%) with PATI <4.0 mu M] between patients treated with a thienopyridine plus a PPI and those without a PPI (14% vs 11%, NS). Conclusion: HPR was frequently observed in Japanese patients treated with thienopyridines plus PPIs compared to those without PPIs. Further prospective studies are needed to estimate the risk of adverse cardiovascular events associated with concomitant use of PPIs and thienopyridines. (C) 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:275 / 282
页数:8
相关论文
共 50 条
  • [21] Does the use of proton-pump inhibitors increase the risk of fracture?
    Clarke, Bart L.
    Amin, Shreyasee
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (08): : 564 - 565
  • [22] Inadequate use of proton-pump inhibitors in patients with liver cirrhosis
    Kalaitzakis, Evangelos
    Bjornsson, Einar
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2008, 20 (06) : 512 - 518
  • [23] Use of Intravenous Proton-Pump Inhibitors in a Teaching Hospital Practice
    Hoover, Jacob G.
    Schumaker, Annabel L.
    Franklin, Kevin J.
    DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (09) : 1947 - 1952
  • [24] Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding
    Yi-Wen Tsai
    Yu-Wen Wen
    Weng-Foung Huang
    Pei-Fen Chen
    Ken N. Kuo
    Fei-Yuan Hsiao
    Journal of Gastroenterology, 2011, 46 : 39 - 45
  • [25] Considerations for long-term use of proton-pump inhibitors
    Garnett, WR
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (21) : 2268 - 2279
  • [26] Inadequate use of proton-pump inhibitors in patients with liver cirrhosis
    Kalaitzakis, Evangelos
    Bjornsson, Einar
    GASTROENTEROLOGY, 2008, 134 (04) : A623 - A623
  • [27] Does the use of proton-pump inhibitors increase the risk of fracture?
    Bart L Clarke
    Shreyasee Amin
    Nature Clinical Practice Endocrinology & Metabolism, 2007, 3 : 564 - 565
  • [28] Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia
    Roughead, Elizabeth E.
    Ramsay, Emmae N.
    Pratt, Nicole L.
    Ryan, Philip
    Gilbert, Andrew L.
    MEDICAL JOURNAL OF AUSTRALIA, 2009, 190 (03) : 114 - 116
  • [29] Proton-pump inhibitors: Three of a kind?
    Bateman, DN
    LANCET, 1997, 349 (9066): : 1637 - 1638
  • [30] Safety profile of the proton-pump inhibitors
    Reilly, JP
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 : S11 - S17